Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics.

ABSTRACT:

Background

The use of tumour xenografts is a well-established research tool in cancer genomics but has not yet been comprehensively evaluated for cancer epigenomics.

Methods

In this study, we assessed the suitability of patient-derived tumour xenografts (PDXs) for methylome analysis using Infinium 450 K Beadchips and MeDIP-seq.

Results

Controlled for confounding host (mouse) sequences, comparison of primary PDXs and matching patient tumours in a rare (osteosarcoma) and common (colon) cancer revealed that an average 2.7% of the assayed CpG sites undergo major (Δβ ≥ 0.51) methylation changes in a cancer-specific manner as a result of the xenografting procedure. No significant subsequent methylation changes were observed after a second round of xenografting between prima

SUBMITTER: Guilhamon P 

PROVIDER: S-EPMC4292812 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature